Actinium Pharmaceuticals
ATNM
42 hedge funds and large institutions have $11.5M invested in Actinium Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 10 closing their positions.
6% more call options, than puts
Call options by funds: $3.01M | Put options by funds: $2.84M
0.6% less ownership
Funds ownership: 9.57% → 8.98% (-0.6%)
2% less funds holding
Funds holding: 43 → 42 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
33% less capital invested
Capital invested by funds: $17.1M → $11.5M (-$5.65M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$500K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$352K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$113K |
| 4 |
VF
Virtu Financial
New York
|
+$105K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$73.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$199K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$158K |
| 3 |
ICP
Interchange Capital Partners
Pittsburgh,
Pennsylvania
|
-$145K |
| 4 |
WANY
Wealthspire Advisors (New York)
New York
|
-$127K |
| 5 |
BC
BIT Capital
Berlin,
Germany
|
-$125K |
ATNM Hedge Fund Activity: Q4 2021 in Review
42 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2021, worth a combined $11.5M — down 33% from $17.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ATNM and 9 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 8 added.
The largest buyer was Endurant Capital Management, opening a new position worth an estimated $500K. The largest seller was Marshall Wace, exiting entirely with an estimated $199K sold.
- 42 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2021, down from 43 in Q3 2021.
- Funds reported $11.5M of Actinium Pharmaceuticals stock for Q4 2021, down 33% quarter-over-quarter.
- 9 funds opened new Actinium Pharmaceuticals positions in Q4 2021 and 10 closed out, a net change of -1 holder.
- The largest Actinium Pharmaceuticals buyer in Q4 2021 was Endurant Capital Management, an estimated $500K added.
- The largest Actinium Pharmaceuticals seller in Q4 2021 was Marshall Wace, an estimated $199K sold.
Based on aggregated 13F filings for Q4 2021.